220461-83-6

Usage

Uses

Used in Pharmaceutical Industry:
4-(1H-PYRAZOL-1-YL)BENZOYL CHLORIDE is utilized as a key reagent in the synthesis of various pharmaceuticals. Its presence in the reaction mixture allows for the formation of new compounds with potential therapeutic applications, making it an essential component in drug discovery and development processes.
Used in Agrochemical Industry:
In the agrochemical sector, 4-(1H-PYRAZOL-1-YL)BENZOYL CHLORIDE is employed as a reagent for the production of agrochemicals. Its ability to participate in organic synthesis reactions is leveraged to create compounds that can be used in the development of pesticides, herbicides, and other agricultural products to enhance crop protection and yield.
Used in Organic Synthesis Research:
4-(1H-PYRAZOL-1-YL)BENZOYL CHLORIDE is also used as a research tool in organic synthesis. Its reactivity and structural features make it a valuable compound for exploring new synthetic pathways and understanding the mechanisms of various chemical reactions.
Safety and Environmental Considerations:
Due to its potential to cause skin and eye irritation, as well as respiratory system irritation upon inhalation, 4-(1H-PYRAZOL-1-YL)BENZOYL CHLORIDE must be handled with care. Additionally, it is classified as toxic to aquatic life, which underscores the importance of proper management and disposal to minimize environmental impact.

InChI:InChI=1/C10H7ClN2O/c11-10(14)8-2-4-9(5-3-8)13-7-1-6-12-13/h1-7H

Upstream product

• 16209-00-0 4-(1H-pyrazol-1-yl)benzoic acid 
• 79-37-8 oxalyl dichloride 

Downstream Products

• 220461-31-4 [4-(Pyrazol-1-yl)-phenyl]-(5H,11H-pyrrolo[2,1-c][1,4]benzodiazepin-10-yl)-methanone 

Relevant academic research and scientific papers

Ammonia as Ultimate Amino Source in Synthesis of Primary Amines via Nickel-Promoted C-H Bond Amination

The direct use of ammonia in transition-metal promoted C-H bond amination for the synthesis of primary amines is considered to be one of the major challenges in synthetic organic chemistry. Herein, we report that such transformation can be successfully ac

Palladium-Catalyzed Decarbonylative Difluoromethylation of Acid Chlorides at Room Temperature

Methods for the direct synthesis of difluoromethylated arenes are sparse, despite the importance of the difluoromethyl group in medical, agro-, and materials chemistry. A palladium-catalyzed decarbonylative cross-coupling reaction of acid chlorides with a difluoromethyl zinc reagent is achieved to access difluoromethylated compounds. The transformation proceeds at room temperature and shows broad functional group tolerance, thus providing a general and efficient method for decarbonylative difluoromethylation of a wide range of aromatic carboxylic acids.

KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor

The present invention relates to compounds of formula (I) that are novel VR1 antagonists useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence, or bladder overactivity.

Vasopressin agonist formulation and process

This invention provides novel formulations for vasopressin agonist compounds, or a pharmaceutically acceptable salt thereof, having the general structure: and processes for making them, the formulations comprising from about 1% to about 20% of active ingredient, from about 1% to about 18% of a surfactant component, from about 50% to about 80% of a component of one or more polyethylene glycols, from about 1% to about 20% of a component of one or more sucrose fatty acid esters and/or polyvinylpyrrolidone and, optionally, one or more preservatives or antioxidants.

Tricyclic vasopressin agonists

This invention relates to new compounds selected from those of the general formula (I), or a pharmaceutically acceptable salt, ester or prodrug form thereof: wherein D, E and G are N or CH, which serve as vasopressin agonists and are useful in treating disorders such as diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders, and the inability to temporarily delay urination and pharmaceutical compositions and methods for same.